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Quality of Life Outcomes Following
Organ-Sparing SBRT in Previously
Irradiated Recurrent Head and Neck
Cancer
Emile Gogineni*, Isabella Zhang, Zaker Rana, Mihaela Marrero, Gurtej Gill,
Anurag Sharma, Adam C. Riegel, Sewit Teckie and Maged Ghaly
Department of Radiation Medicine, Northwell Health, New York, NY, United States
Purpose: To present a retrospective analysis of the efficacy, toxicity, and quality of life
(QoL) of patients treated with OARExtreme-sparing stereotactic body radiotherapy (SBRT)
in previously-irradiated head and neck cancer.
Materials/Methods: From 11/2012 to 7/2015, 60 patients with in-field recurrence of
head and neck cancer underwent re-irradiation with SBRT. Retreatment sites included
the aerodigestive tract (43%), lateral neck (22%), and skull base (35%). The median prior
RT dose was 63.6Gy with a median time from prior irradiation of 16.5 months. The
median volume treated was 61.0 cc. Patients were treated with 40Gy in the definitive
setting or 35Gy in the post-operative setting in five fractions. Dose constraints to the
OARExtreme were calculated with a BED calculator using an alpha/beta ratio of 3 to reduce
the risk of late toxicities. QoL data was collected from patients at the time of consultation
and at subsequent follow up appointments using the MD Anderson Dysphagia Inventory
(MDADI) and Symptom Inventory (MDASI).
Results: The 1- and 2- year rates of local, regional, and distant control and overall
survival were 79/79, 74/70, 74/71, and 59/45%, respectively. Late grade 3 toxicities
were seen in 3% in the group treated to the aerodigestive tract and 1% in the group
treated to the skull base. No grade 4 or 5 toxicities were observed. Patients with skull
base re-irradiation maintained a stable QoL score after radiation treatment, while patients
treated to the aerodigestive tract demonstrated a slight impairment associated with
worsening dysphagia, compared to their pretreatment baseline. All groups experienced
an increase in xerostomia.
Conclusions: OARExtreme-sparing SBRT is able to achieve excellent tumor coverage
while protecting the organs at highest risk of re-irradiation-related complications. The
potential for lower toxicities and maintained QoL with this treatment makes it a promising
option for salvage of recurrent head and neck cancer.
SUMMARY
Local control and overall survival rates for recurrent head and neck cancer remain poor,
despite the use of local therapy. In addition, re-irradiation with conventional radiation
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therapy confers a high rate of grade 3 and higher late toxicities. SBRT appears to improve
the therapeutic ratio in this patient population, and treatment planning with a focus on
sparing OARExtreme may further decrease the rates of morbidity in these patients.
Keywords: SBRT, head and neck cancer, quality of life, stereotactic, radiosurgery, SABR
INTRODUCTION
Locoregional recurrence within a previously-irradiated field
represents a significant barrier in the long-term control of head
and neck cancer, with a high rate of morbidity and mortality
associated with local disease. Maximal surgical resection at
the time of recurrence continues to represent the standard
of care with adjuvant radiation considered when the risk of
further recurrence is extremely high. Regardless, most patients
are not surgical candidates due to their extent of tumor
recurrence or other comorbidities limiting their ability to tolerate
the operation (1). Both chemotherapy and conventionally
fractionated radiation therapy have been used for recurrent,
unresectable disease, with a median survival ranging from 6
to 9 months, with rates of grade 3 and higher late toxicities
approaching 40% (2, 3).
Over the last decade, stereotactic body radiation therapy
(SBRT) has been increasingly used for irradiation of recurrent
head and neck cancer, both in the definitive and adjuvant
settings. Recent studies have demonstrated the relatively low
rates of severe toxicities with SBRT in the re-irradiation
setting, but without a substantial improvement in overall
survival compared to conventionally fractionated radiation
therapy (4–6).
The purpose of aggressive locoregional recurrence is two-
fold: first, locoregional disease is a leading cause of mortality
in head and neck cancer and treatment of the recurrence
may prolong survival (7). Second, tumor recurrence can cause
significant symptoms, including pain, dysphagia, and cranial
nerve deficits, which can be reduced by radiation. The goals
of local control and palliation must then be balanced against
the potential long-term risks of re-irradiation that could
impair quality of life (QoL). In this study, we present the
results of re-irradiation of in-field recurrence of head and
neck cancer using SBRT while prioritizing specific normal
tissue tolerances. The protection of normal tissues has become
increasingly important as technology and patient outcomes
improve and patients present with locoregional disease months
or years after re-irradiation, and may require a second course
of retreatment.
MATERIALS AND METHODS
Approval was obtained from the CSSRC (Cancer Services
Scientific Review Committee) and the IRB (IRB #15-089). The
Informed Consent and HIPAA authorization were waived, given
that it was a retrospective chart review and the fact that no
PHI was reported. Sixty patients were treated in our institution
with re-irradiation to a previously irradiated site—either in
the definitive or post-operative setting—between March 2013
and July 2015. Patients included in this analysis had at least
6 months follow up or until their time of death if this was
<6 months. SBRT was delivered with a particular focus on
sparing organs at extreme risk (OARExtreme), i.e., organs that
approached their maximal radiation tolerance after the initial
course of radiation and had a high potential to significantly
impair a patient’s QoL if toxicity were to occur in that site.
Patients were simulated with standard immobilization of a
thermoplastic head and neck mask. Simulation CT without
IV contrast was obtained with a 2-mm slice thickness and
MRI and/or PET images were fused at the discretion of the
treating physician. In addition, delivered dose plans from the
initial course of radiation were deformably registered to the
new CT (Figure 1) using the deformable image algorithm from
VelocityTM. The gross tumor volume (GTV) was defined by
gross tumor seen on imaging studies and/or clinical exam. All
gross disease i.e., primary and nodal recurrence, was treated.
In the setting of postoperative radiation, the tumor bed (based
on preoperative imaging, preoperative physical exam/endoscopy,
operative findings, pathologic findings) plus region(s) of grossly
involved lymphadenopathy was defined as the clinical target
volume (CTV). No additional margin was added for the planning
target volume (PTV) in order to limit toxicity. Doses of 40Gy
and 35Gy were prescribed in the definitive or post-operative
setting, respectively. Daily cone-beam CT and kV imaging
was used in order to account for inter-fractional variations.
The prioritized OARExtreme were dependent on the site of
re-treatment: the cranial nerve foramen and skull base bony
structures were prioritized in patients receiving radiation to
skull base recurrences. In patients receiving radiation to the
aerodigestive tract (AD), special attention was paid to the
laryngeal cartilage and mandible. With lateral neck radiation,
the brachial plexus and carotid arteries were prioritized. The
distribution of doses to the OARExtreme were estimated using
the deformably registered doses on the CT simulation scan.
The total allowable doses to the OARExtreme were based on
the EMAMI tables and RTOG head and neck protocols and
calculated to its biologically equivalent dose using an α/β ratio
of 3 (BED3) to estimate the risk of late toxicities to the normal
tissues. See Table 1 for a list of prioritized constraints. Given
the palliative intent of treatment, meeting OAR constraints
took priority over PTV coverage in instances where both were
not possible.
Treatment was delivered twice a week for a total of five
fractions via volumetric art therapy (VMAT) with cone-
beam CT imaging before each treatment and in between
each delivered arc. During image-guided treatment, the
OARExtreme, was used as the fusion surrogate. Concurrent
systemic therapy was delivered at the discretion of the treating
medical oncologist.
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FIGURE 1 | Deformable registration of initially delivered radiation doses onto
retreatment planning CT. The yellow arrow highlights the PET-positive tumor.
The top panel shows fusion of doses onto CT based on anatomical landmarks
before deformable registration. The bottom panel shows deformably registered
images with better delineation of doses delivered to normal tissue structures.
Our goal was to evaluate the efficacy and toxicity of treatment
with OARExtreme-sparing SBRT, as well as the effects of treatment
on patient-reported QoL. QoL was assessed with several
validated questionnaires: the M. D. Anderson Dysphagia
Inventory (MDADI), the Symptom Inventory—Head and Neck
Module (MDASI-HN), and the Xerostomia Questionnaire.
Patients were asked to fill out all three questionnaires at
their initial consult and subsequent follow up visits. The
MDADI includes 20 questions that assess a patient’s global,
functional, emotional, and physical status. Scores range from
0 to 100, where 100 represents no impairment within the
subscale. The MDASI-HN assesses the severity of a range
of symptoms, including pain, fatigue, sadness, swallowing,
speaking, nausea and vomiting, and insomnia, where each
symptom can be rated from 0 to 10 (10 representing the most
severe symptoms). The second section of the MDASI-HN
assesses overall QoL by addressing symptom interference
with daily function. Each question was also scored from
0 to 10, with 10 representing complete interference. The
Xerostomia Questionnaire assesses difficulty talking, chewing,
and swallowing due to dryness, as well as mouth/throat
dryness during particular activities and the need for
drinking liquids.
TABLE 1 | Constraints.
OAR Constraint
PTV D95% = 98–100%
Larynx Mean dose < 15 Gy
Mandible Max dose < 20 Gy
Spinal cord/brainstem Cumulative max dose <
54Gy equivalent in 2 Gy/fx
Or Max dose < 8Gy (if
records not available)
Cochlea Mean dose < 15 Gy
Retina Mean dose < 15 Gy
Lens Max dose < 5 Gy
Carotid aa Max dose < 32.5 Gy
Optic nerve/chiasm Max dose < 25 Gy
Temporal tips Mean dose < 5 Gy
Skin D (10 cc) < 39.5 Gy
Thyroid lamina Max dose < 30 Gy
Patients were seen on treatment every week with acute
toxicities scored based on the CTCAE 4.0 scale. Follow up
after treatment was performed around 4–6 weeks, unless the
patient had acute side effects that required earlier follow
up. Regular follow up with the medical oncologist and/or
head and neck surgeon was also recommended. CT or MR
imaging was ordered 6 weeks after radiation completion
and every 3 months afterwards for surveillance. PET/CT
imaging was ordered if clinically indicated. Late toxicities were
assessed at follow up appointments and scored based on the
RTOG schema.
Statistical Methods
Overall survival and time to progression, and time to
progression or death (each measured from completion of
SRS) were calculated using the Kaplan-Meier Method with
statistical analyses performed in SPSS. P-values <0.05 were
considered significant.
RESULTS
Patient and Treatment Characteristics
A chart review of patients treated with SBRT in our department
between the dates of November 2012 and July 2015 revealed 60
patients with a total of 69 sites treated (one patient with two sites
treated concurrently and all eight additional sites were treated
after a second failure). All patients had at least 6 months of follow
up unless death occurred before 6 months. The median follow up
time was 9.3 months.
Baseline patient demographics are summarized in Table 2.
Thirty two (53%) patients underwent surgery for tumor
recurrence. Thirty nine (57%) of patients received concurrent
systemic therapy with SBRT, with a combination carboplatin and
paclitaxel as the most frequently delivered regimen. Fifty one
(74%) of the treated tumors were squamous cell carcinoma. Other
histologies included adenocarcinoma, adenoid cystic carcinoma,
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TABLE 2 | Characteristics of patients treated with OARExtreme-sparing SBRT.
Patient characteristics Number
Total patients 60
Total sites treated 69
Patients with regional recurrence
requiring re-SBRT
9
Gender
Male 39 (70%)
Female 21 (30%)
Median age in years (range) 70 (48–88)
Median initial radiation dose in Gray 63.6
Median interval from prior irradiation
in months
16.5
Surgery at recurrence 32 (53%)
Concurrent systemic therapy with
SBRT
39 (57%)
Carboplatin/paclitaxel 20
Cetuximab 6
Carboplatin/paclitaxel/cetuximab 1
Cisplatin 3
Carboplatin/pemetrexed 2
Other/unknown 7
Histology
Squamous cell carcinoma 51 (74%)
Adenocarcinoma 4 (6%)
Other 14 (20%)
SBRT site
Aerodigestive tract (AD) 30 (43%)
Lateral neck (LAT) 15 (22%)
Skull base 24 (35%)
SBRT dosimetry
Median treatment volume in cc 61.0
Median V90 98.4%
Median D90 99.0%
Median follow-up in months 9.3
basal cell carcinoma, thyroid carcinoma, and sarcoma. Patients
with squamous cell carcinoma were treated with concurrent
cetuximab at the discretion of the medical oncologist. Patients
were divided into three categories based on the anatomical site
of recurrences, for more specific reporting of treatment-related
toxicities and QoL. These sites were the aerodigestive tract (43%),
lateral neck (22%), and skull base (35%). If recurrence involved
overlap of multiple groups, patients were included in the group
in which the largest volume of disease was treated. Treatment of
the nasopharynx was defined as skull base. Despite prioritizing
OAR constraints over PTV coverage, the median D90 was 99.0%
and the median V90 was 98.4%.
Tumor Control and Survival
Tumor control was assessed based on imaging and clinical
findings. CT and/or MR imaging was routinely performed for
follow upwith PET/CT used for suspicious radiographic findings.
The 1- and 2- year rates of local control were 79 and 79%,
respectively. The median time to local failure was 43 months.
The 1- and 2- year rates of regional control were 74 and 70%.
The median time to regional failure was 36 months. The 1-
and 2- year rates of distant control were 74 and 71%. The
median time to distant failure was 36 months. The 1- and 2-year
rates of overall survival were 59 and 45%. The median survival
was 23 months. There was no statistically significant difference
in median survival for patients who received chemotherapy at
the time of recurrence vs. those who did not (12.93 mo vs.
11.33 mo, p = 0.82), or those who underwent surgery for their
recurrent disease vs. no surgery (10.93 mo vs. 12.97 mo, p =
0.77). There was no difference in overall survival between groups
based on anatomic location (p= 0.58) (Figure 2). There were no
significant differences in local control or overall survival based on
the site of irradiation.
Second Recurrences
Eight patients had second recurrences of cancer within the
initially irradiated field, with or without overlap onto the field
receiving SBRT, and received re-irradiation with SBRT to a
second site. The prescribed dose for the second course of
re-irradiation was the same as primary re-irradiation, with
40Gy prescribed in the definitive setting and 35Gy in the
post-operative; however, doses could be lowered if normal
tissue tolerances could not be met. The median survival
after re-treatment with SBRT was 6.57 months (range 1.40–
21.57 months).
Toxicity
Three patients (4%) experienced grade 3 late toxicity, including
osteoradionecrosis (1 patient), chondroradionecrosis (1 patient),
and osteomyelitis (1 patient). Two of the toxicities occurred
in patients being treated to the aerodigestive tract, while one
occurred in a skull base retreatment. There were no other
variables significantly associated with toxicity rates. No grade 4
or 5 late radiation toxicities were observed in the study group.
Quality of Life
The MDADI responses demonstrated that patients with re-
irradiation to the skull base, maintained stable dysphagia-
associated scores from pre-treatment to long-term follow up.
Patients with retreatment to the aerodigestive tract demonstrated
a slight decrease in global scores, correlating with the increase
in symptoms seen on the MDASI, before returning near
baseline. The MDASI-HN showed an increase in patient-
reported symptoms in the acute time period after treatment in the
skull base group, with a longer period to symptom development
in patients treated to the aerodigestive tract. The QoL scores
assessed with this metric followed closely with symptoms cores
with a small decrease in QoL before returning closer to baseline
(Figures 3, 4). Patients in all three groups demonstrated an
increase in xerostomia scores after treatment; however, there was
a trend to an improvement in xerostomia patients in patients
in the skull base group in long term follow up. There were
not enough patients with re-irradiation to the lateral neck who
completed pre- and post-treatment questionnaires to analyze this
site-specific QoL data. There were no other captured variables
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FIGURE 2 | Overall survival of patients after completion of SBRT. There was no statistically significant difference in survival between groups based on site of
recurrence.
FIGURE 3 | MD Anderson Symptom Inventory Scores: symptoms scores (Left) and Quality of Life scores (Right). Symptom scores range from 0 to 200 where 200
represents the most symptom interference with daily life. Quality of life scores range from 0 to 60 where 60 represents the most interference of symptoms on quality of
life metrics.
associated with QoL metrics, such as use of chemotherapy,
volume irradiated, or use of surgery before SBRT.
DISCUSSION
Locoregional control of head and neck cancer continues to
remain a primary challenge in head and neck cancer with
half of patients dying of localized disease (8, 9). Resection of
localized recurrence has demonstrated long-term local control
rates of 25–45%; however, over half of these patients will
recur locally (10–13). Patients at a high risk of recurrence,
such as with residual disease or extracapsular extension of
nodal disease, may be recommended to undergo postoperative
re-irradiation. In a phase III study patients with recurrent
disease in a previously-irradiated field underwent surgery
followed by either conventionally fractionated chemoradiation
or observation. Disease free survival in the adjuvant radiation
group was improved; however, significant high grade toxicities
were observed (28% patients with grade 3 and 39% with late
grade 4 toxicities) with no improvement in overall survival (14).
This study serves as the foundation for recommending adjuvant
chemoradiation but demonstrates the high rate of morbidity
associated with treatment.
For non-surgical candidates, definitive chemoradiation can be
offered with the intent to obtain long term tumor control. Re-
irradiation with conventional fractionation to a dose of 60Gy in
40 BID fractions, as per RTOG 9610, resulted in nearly a 20%
rate of late grade 3 toxicities and 3% late grade 4 toxicities. The
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FIGURE 4 | MD Anderson Dysphagia Inventory Subscale Scores (Global, Functional, Physical, and Emotional). Scores range from 0 to 100 where 100 represents the
least interference with daily life. Individual patient scores (faint colors) and smoothed fitted curve (blue) are shown.
1- and 2- year overall survival rates of this group were 42 and
17% with a median survival of 8.5 months (2). Compared to 3D
techniques, IMRT has improved the rate of local control in the
re-irradiation setting (52% vs. 20% at 2 years); however, even with
IMRT, the doses that can be delivered are significantly limited by
constraints set by the prior course of radiation. With advances
in imaging and image guided radiation therapy, larger doses per
fraction and smaller margins can be used, and SBRT has been
shown in retrospective studies to improve local control. Phase I
and II trials have also demonstrated the safety of using SBRT up
to a dose of 44Gy in 5 fractions in the re-irradiation setting, as
well as decreased toxicity in comparison to historical data from
conventional radiotherapy (15).
Previously published outcomes of SBRT for retreatment have
demonstrated local control rates of 30–80% at 1–2 years with
overall survival rates of 20–60% at the same time interval (5, 16).
Vargo et al. published data on the use of adjuvant re-irradiation
with SBRT for patients with positive margins and/or extranodal
extension and found a 1 year locoregional control rate of
51% and survival rate of 64% (17). The rates of late severe
toxicities were lower than with conventional re-irradiation, with
8% experiencing grade 3 or higher toxicities. Our data shows
comparable rates of local control as compared to previous studies
of SBRT for recurrences; however, patients in our group were
treated to substantially larger tumor volumes, which have been
correlated with decreased tumor control (18).
Recurrences after SBRT for re-irradiation are not uncommon,
with reported rates up to 59% in the literature (5). In the series
presented by Vargo et al., 23% of the patients who were re-
irradiated with SBRT and concurrent cetuximab developed a
nodal recurrence, for which they were again re-irradiated with
SBRT (17). In our series, 15% of patients received repeat SBRT
for locoregional recurrences, with a median survival of over
6 months after their second course of retreatment. As patient
survival increases and local treatment improves, regional failures
begin to play a larger role in long-term tumor control and
symptoms. Repeat SBRT for re-irradiation has not been widely
performed and longer-term data is needed to address the safety
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and toxicity associated with multiple courses of hypofractionated
radiation; however, if patients are to be candidates for repeat re-
irradiation, then extra caution should be applied to the normal
tissues, as the risks for radiation-induced injury increase.
The incidence of late toxicities from re-irradiation with SBRT
are substantially lower than those seen with older techniques;
however, there are still significant and life-threatening toxicities
associated with treatment. A recently published 10-year update
of toxicities from SBRT re-irradiation showed 18.9% of
patients experiencing late grade ≥3 toxicities, with significantly
higher rates of severe toxicity in patients retreated to the
larynx/hypopharynx and when doses ≥44Gy were used (19).
One of the most morbid toxicities associated with re-irradiation
is carotid blow-out syndrome (CBOS), which was seen in 3–
17% of patients retreated with SBRT and usually presents within
10 months of retreatment (5). Yazici et al. also published their
institutional experience with carotid blow out syndrome and
demonstrated that treatment every other day and doses <34Gy
reduce the rate of CBOS (20). At our institution, the total
allowable maximum dose to the carotid was 32.5Gy, with
treatments delivered twice a week, and no patients within our
cohort developed a carotid blow out. We would propose that this
constraint should be strictly followed even if this compromises
PTV coverage.
The toxicities from radiation have also been shown to play
a significant role in decreasing the QoL in patients undergoing
palliative treatment. Irradiation to the head and neck with
conventional techniques has been shown to cause significant
mucositis and dysphagia, causing pain, and decreased oral intake
(2, 7). In addition, conventional fractionation is associated with
facial and neck edema. This was not observed in patients
receiving SBRT in our cohort. This was likely due to our
attempt to limit the amount of sub-parenchymal normal tissue
in our field, in addition to the lack of margin added to GTV
and the use of only twice-weekly radiation. Even with the
use of SBRT in delivery of re-irradiation, patient reported
QoL decreased in up to 50% of patients (15). However, there
seems to have been an improvement in treatment delivery as
recent publications show unchanged QoL scores after treatment
(17). In our study, patient-reported QoL data was collected
at the time of consultation and in follow up. While the
data appears to demonstrate an increase in symptoms in the
first month after treatment, the MDADI-assessed QoL assessed
appears to remain stable in both short- and long-term follow
up. It is important to note that even as the spline shows
stability of scores (Figures 3, 4), individual patient responses
were quite varied with some patients demonstrating dramatic
improvements while others experiences a long-term decrease
in QoL.
Our study has several important limitations. First, it is a
retrospective study on a non-randomized cohort of patients from
a single institution, treated by a single physician. Second, despite
only including patients who had at least 6 months follow up,
the median follow up time was <1 year, which is not entirely
enough time to rule out the development of any further grade
3 and higher toxicities. Several papers evaluating the use of
SBRT in the setting of re-irradiation have described a higher
rate of severe toxicities after longer term follow up and one
publication describes a continuous increase in the rate of late
toxicities more than 5 years after treatment (19, 21, 22). The low
rate of late toxicities seen in this population are promising, but
significantly longer follow up of long-term survivors is important
to evaluate for tissue damage associated with re-irradiation.
Third, not all patients completed the MDADI, MDASI, and/or
XQ prior to and after treatment. Patients who completed the
surveys may represent a selection bias. This potential bias, as well
as the inherent problems of reliability in intra-rater perception, is
important to consider in evaluating the QoL data.
CONCLUSION
Based on the results seen in this retrospective study, OARExtreme-
sparing SBRT is able to achieve comparable local control
and overall survival rates as previously published data for
re-irradiation of head and neck cancer. Despite prioritizing
meeting the constraints of the OARExtreme over PTV coverage,
high quality plans with excellent coverage of the PTV were
able to be created. The potential for lower toxicities with
maintained tumor control and QoL using OARExtreme-sparing
SBRT provides a promising salvage treatment for patients with
in-field recurrences of head and neck cancer and preserves a
treatment option of repeat re-irradiation if patients develop a
second in-field recurrence.
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